Crescendo Biologics

Crescendo has developed a unique transgenic mouse which generates fully human VH single domain antibody fragments in the absence of contaminating murine light chains.

VH are the smallest, most robust antibody fragments with advantages for engineering of bispecific and multivalent products, tissue and tumour penetration, topical delivery and simple manufacture.  

Crescendo is applying the platform to a pipeline focused on inflammation and oncology, and topical delivery.

Company type
Dr Matthew Roe
Chief Business Officer 

Domainex United Kingdom

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates already in clinic.

Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focussed and integrated approach to medicinal chemistry and computational chemistry. These technologies and Domainex’s approach also enable it to successfully tackle a greater range of drug target classes, such as kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions.

 Domainex has applied its unique technologies and focussed discovery approach to enable it to develop its own pipeline of oncology drugs, including inhibitors of the kinases IKKε/TBK1 for both oncology and inflammation and a number of epigenetics related lysine methyltransferases, including G9a

Company type
Dr Eddy Littler
Chief Executive Officer 
Dr Joanne McCudden
Head of Business Development 

e-therapeutics United Kingdom

e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company’s discovery and development activity is focused in cancer and disorders of the nervous system. The firm has two drugs in the clinic: ETS2101, which is in phase I trials for cancer; and ETS6103, which is in phase II trials for major depressive disorder. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.  

Company type
Dr Daniel Elger
Dr Daniel Elger
LinkedIn logo Chief Financial Officer 

MGB Biopharma United Kingdom

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise.

Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections.

MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

Company type
Dr Miroslav Ravic
Mr Raymond Spencer